{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:50:51Z","timestamp":1759366251344,"version":"build-2065373602"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T00:00:00Z","timestamp":1710892800000},"content-version":"am","delay-in-days":354,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.ejmech.2023.115257","type":"journal-article","created":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T22:14:53Z","timestamp":1678918493000},"page":"115257","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Structure-activity relationships of actively FhuE transported rifabutin derivatives with potent activity against Acinetobacter baumannii"],"prefix":"10.1016","volume":"252","author":[{"given":"M.","family":"Maingot","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Bourotte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.C.","family":"Vetter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Schellhorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Antraygues","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Scherer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Gitzinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Kemmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.E.","family":"Dale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Defert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Lociuro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Br\u00f6nstrup","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Willand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Trebosc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2023.115257_bib1","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine)","volume":"28","author":"Paul","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.ejmech.2023.115257_bib2","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1093\/cid\/ciab1013","article-title":"Infectious diseases society of America guidance on the treatment of AmpC \u03b2-lactamase\u2013producing enterobacterales, carbapenem-resistant acinetobacter baumannii, and stenotrophomonas maltophilia infections","volume":"74","author":"Tamma","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ejmech.2023.115257_bib3","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.cmi.2022.01.030","article-title":"IDSA guidance and ESCMID guidelines: complementary approaches toward a care standard for MDR Gram-negative infections","volume":"28","author":"Lawandi","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.ejmech.2023.115257_bib4","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","author":"Murray","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2023.115257_bib5","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.ajic.2019.03.003","article-title":"Predictors of mortality in patients infected with carbapenem-resistant Acinetobacter baumannii: a systematic review and meta-analysis","volume":"47","author":"Du","year":"2019","journal-title":"Am. J. Infect. Control"},{"key":"10.1016\/j.ejmech.2023.115257_bib6","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S1473-3099(18)30605-4","article-title":"Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis","volume":"19","author":"Cassini","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ejmech.2023.115257_bib7","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01991-21","article-title":"Analysis of the clinical pipeline of treatments for drug-resistant bacterial infections: despite progress, more action is needed","volume":"66","author":"Butler","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2023.115257_bib8","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","article-title":"Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis","volume":"18","author":"Tacconelli","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ejmech.2023.115257_bib9","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1038\/s41564-020-0737-6","article-title":"A nutrient-limited screen unmasks rifabutin hyperactivity for extensively drug-resistant Acinetobacter baumannii","volume":"5","author":"Luna","year":"2020","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.ejmech.2023.115257_bib10","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1016\/j.drudis.2021.07.001","article-title":"Rifabutin for infusion (BV100) for the treatment of severe carbapenem-resistant Acinetobacter baumannii infections","volume":"26","author":"Trebosc","year":"2021","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2023.115257_bib11","article-title":"Design and synthesis of water-soluble prodrugs of rifabutin for intravenous administration","volume":"114515","author":"Antraygues","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115257_bib12","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S0092-8674(01)00286-0","article-title":"Structural mechanism for rifampicin inhibition of bacterial rna polymerase","volume":"104","author":"Campbell","year":"2001","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2023.115257_bib13","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1093\/jac\/31.5.799-a","article-title":"Comparative activity of rifabutin and rifampicin against gram-negative bacteria that have damaged or defective outer membranes","volume":"31","author":"Vaara","year":"1993","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejmech.2023.115257_bib14","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1093\/jac\/dkaa370","article-title":"In vitro activity of rifabutin against 293 contemporary carbapenem-resistant Acinetobacter baumannii clinical isolates and characterization of rifabutin mode of action and resistance mechanisms","volume":"75","author":"Trebosc","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"year":"2021","series-title":"In Vivo Efficacy of BV100 in Mouse Models of Acinetobacter Baumannii Infection","author":"Dale","key":"10.1016\/j.ejmech.2023.115257_bib15"},{"key":"10.1016\/j.ejmech.2023.115257_bib16","doi-asserted-by":"crossref","first-page":"e00920","DOI":"10.1128\/msphere.00920-21","article-title":"In vitro activity of rifabutin and rifampin against antibiotic-resistant acinetobacter baumannii, Escherichia coli, Staphylococcus aureus, Pseudomonas aeruginosa, and Klebsiella pneumoniae","volume":"6","author":"Lee","year":"2021","journal-title":"mSphere"},{"key":"10.1016\/j.ejmech.2023.115257_bib17","first-page":"94","article-title":"Rifamycins--obstacles and opportunities","volume":"90","author":"Aristoff","year":"2010","journal-title":"Tuberc. Edinb. Scotl."},{"key":"10.1016\/j.ejmech.2023.115257_bib18","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.cell.2005.07.014","article-title":"Allosteric modulation of the RNA polymerase catalytic reaction is an essential component of transcription control by rifamycins","volume":"122","author":"Artsimovitch","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2023.115257_bib19","doi-asserted-by":"crossref","first-page":"5717","DOI":"10.1016\/j.bmcl.2006.08.090","article-title":"New rifabutin analogs: synthesis and biological activity against Mycobacterium tuberculosis","volume":"16","author":"Barluenga","year":"2006","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115257_bib20","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00959-19","article-title":"In vitro activity of rifampin, rifabutin, rifapentine, and rifaximin against planktonic and biofilm states of staphylococci isolated from periprosthetic joint infection","volume":"63","author":"Albano","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2023.115257_bib21","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1093\/jac\/42.5.597","article-title":"Accumulation of rifampicin by Escherichia coli and Staphylococcus aureus","volume":"42","author":"Williams","year":"1998","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejmech.2023.115257_bib22","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/sj.emboj.7600499","article-title":"Structural, functional, and genetic analysis of sorangicin inhibition of bacterial RNA polymerase","volume":"24","author":"Campbell","year":"2005","journal-title":"EMBO J."},{"key":"10.1016\/j.ejmech.2023.115257_bib23","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.molcel.2018.08.028","article-title":"Mode of action of kanglemycin A, an ansamycin natural product that is active against rifampicin-resistant Mycobacterium tuberculosis","volume":"72","author":"Mosaei","year":"2018","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejmech.2023.115257_bib24","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1021\/acs.analchem.8b03586","article-title":"Subcellular quantification of uptake in gram-negative bacteria","volume":"91","author":"Prochnow","year":"2019","journal-title":"Anal. Chem."},{"key":"10.1016\/j.ejmech.2023.115257_bib25","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1021\/acs.accounts.0c00895","article-title":"Facilitating compound entry as a means to discover antibiotics for gram-negative bacteria","volume":"54","author":"Mu\u00f1oz","year":"2021","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.ejmech.2023.115257_bib26","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/s41579-019-0294-2","article-title":"Porins and small-molecule translocation across the outer membrane of Gram-negative bacteria","volume":"18","author":"Vergalli","year":"2020","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.ejmech.2023.115257_bib27","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/nyas.14134","article-title":"Permeability barriers of Gram-negative pathogens","volume":"1459","author":"Zgurskaya","year":"2020","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.ejmech.2023.115257_bib28","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1021\/acssynbio.8b00430","article-title":"Deconstructing cell-free extract preparation for in vitro activation of transcriptional genetic circuitry","volume":"8","author":"Silverman","year":"2019","journal-title":"ACS Synth. Biol."},{"issue":"7","key":"10.1016\/j.ejmech.2023.115257_bib29","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1093\/bioinformatics\/btq054","article-title":"Skyline: an open source document editor for creating and analyzing targeted proteomics experiments","volume":"26","author":"MacLean","year":"2010","journal-title":"Bioinformatics"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423002234?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423002234?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:49:26Z","timestamp":1759330166000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523423002234"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":29,"alternative-id":["S0223523423002234"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115257","relation":{},"ISSN":["0223-5234"],"issn-type":[{"type":"print","value":"0223-5234"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Structure-activity relationships of actively FhuE transported rifabutin derivatives with potent activity against Acinetobacter baumannii","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115257","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115257"}}